How Is The Non-Alcoholic Steatohepatitis Biomarkers Market Expected To Grow At 22.6% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Non-Alcoholic Steatohepatitis Biomarkers Market In The Coming Years?
The market size of biomarkers for non-alcoholic steatohepatitis has seen a substantial boost in recent times. It is predicted to leapt from $1.36 billion in 2024 to a staggering $1.68 billion in 2025, boasting a compound annual growth rate (CAGR) of 23.9%. The historic growth can be credited to factors such as diabetes and metabolic syndrome, consciousness and screening initiatives, limitations of liver biopsy, regulatory backing, inclination towards personalized treatment, along with clinical trials in NASH.
The market size for non-alcoholic steatohepatitis biomarkers is projected to experience remarkable growth in the coming years, reaching $3.81 billion by 2029 with a compound annual growth rate (CAGR) of 22.6%. This growth expected in the forecast period is due to factors such as the introduction of new therapies, broader implementation of precision medicine practices, patient advocacy measures, the integration of multi-omics data, and increased emphasis on patient engagement. Some of the key trends predicted to impact this market during the forecast period include telemedicine and remote monitoring, advanced diagnostic platforms, global research collaborations, technological progress in biomarker discovery, the adoption of artificial intelligence (AI), and the incorporation of imaging biomarkers.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
What Drivers Are Accelerating Expansion Of The Non-Alcoholic Steatohepatitis Biomarkers Market?
The increasing incidence of liver cancer is projected to bolster the expansion of the non-alcoholic steatohepatitis biomarkers market. Liver cancer involves the formation of malignant tumors in the liver, originating either within the liver (primary liver cancer) or spreading from other body parts (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers play a vital role in liver cancer for the early detection, monitoring the progression of the disease, evaluating the response to treatment, as well as providing prognostic information, thereby minimizing the necessity for invasive procedures. For example, the World Cancer Research Fund, a not-for-profit organization based in the UK, reported about 866,136 new liver cancer cases globally in 2022, making it the 6th most prevalent cancer worldwide. As a result, the rising incidence of liver cancer is fueling the non-alcoholic steatohepatitis biomarkers market’s growth.
How Is The Global Non-Alcoholic Steatohepatitis Biomarkers Market Broken Down By Segment?
The non-alcoholic steatohepatitis biomarkersmarket covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Which Trends Are Likely To Redefine Growth Paths In The Non-Alcoholic Steatohepatitis Biomarkers Market?
Gaining traction in the non-alcoholic steatohepatitis biomarkers market is the trend of technological enhancements. The primary companies in this market are concentrating on creating innovative solutions to consolidate their market standing. For instance, in October 2022, an agreement was reached between GENFIT, a late-stage biopharmaceutical company from France, and LabCorp, a US-based life sciences company. They engaged in an exclusive five-year license deal for GENFIT’s NIS4 technology, devised to identify patients at risk of non-alcoholic-steatohepatitis (NASH). This NIS4 technology is a novel, multi-biomarker-based algorithm that caters exclusively to the identification of patients with NASH and significant to advanced fibrosis (F > 2), otherwise known as at-risk NASH. As per the agreement, LabCorp is to develop and market a blood-based molecular diagnostic test that utilizes NIS4 technology in the US and Canada, providing extensive access for healthcare professionals.
Which Firms Are Making The Biggest Impact In The Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Non-Alcoholic Steatohepatitis Biomarkers Market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2025, By The Business Research Company
Site Remediation Consulting Services Global Market Report 2025
Psoriasis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Scientific Research And Development Services Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
